Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz

Precision Therapeutics (NASDAQ:AIPT) announced that its chief executive officer and director, Carl Schwartz, has made an additional investment of $1,000,000 in the Company, effective January 8, 2019.

As quoted in the press release:

“I have long been a firm believer in the vast potential of Precision Therapeutics and my most fervent demonstration of this belief is expressed through my investment in the company and my decision to receive compensation for my executive roles in the form of equity in lieu of cash.  I am pleased with our use of capital and confidently invest in Precision Therapeutics to demonstrate my long-term commitment to our mission and our investors,” commented Dr. Schwartz.  “I am extremely proud of the evolution of our company, from the initial development of the Skyline Medical business, to the pending acquisition of Helomics, the initiation of the development of products by our TumorGenesis subsidiary, and other progress in the development of the company’s contract research organization business, which have brought us to where the company stands today.  I remain more convinced than ever that Precision Therapeutics will continue to create value for investors while providing essential products for human health, including AI-driven oncology treatment, top-tier clinical research resources and providing safer work environments wherever medical procedures are performed.”

To be added to the Precision Therapeutics’ database, please email Info@MoneyInfo-llc.com with your email address.  This is solely for the use of Precision Therapeutics and will not be sold or distributed to third parties.

Click here to read the full press release.